

# CD19

Catalog # PVGS1921

## Product Information

---

<b>Primary Accession Species</b>	<a href="#">P15391-1</a> Human
<b>Sequence</b>	Pro20-Lys291
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	60.1 kDa
<b>Formulation Reconstitution</b>	Lyophilized from a 0.22 $\mu$ m filtered solution in PBS, (pH 7.4). Centrifuge the tube before opening. Reconstituting to a concentration more than 100 $\mu$ g/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## Additional Information

---

<b>Target Background</b>	CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
--------------------------	--

## Protein Information

---

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.